Online citations, reference lists, and bibliographies.
← Back to Search

Medicinal Inorganic Chemistry: Metal‐containing Diagnostic Compounds

K. Thompson
Published 2011 · Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Metallopharmaceuticals designed for use in diagnostic compounds cover a broad spectrum of diagnostic modalities, starting with barium sulfate for enhanced X-ray contrast, to the hugely successful gadolinium-based magnetic resonance imaging (MRI) contrast agents, to more recent advances in positron emission tomography (PET) and single photon emission computed tomography (SPECT) requiring radiolabeled metal-based diagnostic agents for image detection. In each case, the pharmacokinetics of tissue distribution and the thermodynamic stability of the metal-ligand coordination complex are very important to the clinical utility of the particular compound. For radiolabeling, the speed and ease of radiolabel production are also key features of the metallodiagnostic agent's utility. Keywords: MRI; contrast agent; SPECT; PET; rubidium; gadolinium; 64Cu; 68Ga; 67Ga; 18F; 99mTc; bifunctional metallopharmaceutical
This paper references
10.1038/242190a0
Image Formation by Induced Local Interactions: Examples Employing Nuclear Magnetic Resonance
P. Lauterbur (1973)
10.1021/CR00081A003
Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design
R. Lauffer (1987)
10.1021/IC00299A011
Solution structure and dynamics of lanthanide(III) complexes of diethylenetriaminepentaacetate: a two-dimensional NMR analysis
B. Jenkins (1988)
10.1016/0730-725X(90)90055-7
The relationship between thermodynamics and the toxicity of gadolinium complexes.
W. Cacheris (1990)
10.1016/0002-9149(91)90456-U
Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease.
R. Stewart (1991)
10.1016/0730-725X(92)90016-S
Dissociation of gadolinium chelates in mice: relationship to chemical characteristics.
P. Wedeking (1992)
10.1021/CR00019A013
Coordination compounds in nuclear medicine
S. Jurisson (1993)
10.1021/JA00132A025
Gadolinium complex of tris[(3-hydroxy-1-methyl- 2-oxo-1,2-didehydropyridine-4-carboxamido)ethyl]-amine: A New Class of gadolinium magnetic resonance relaxation agents
J. Xu (1995)
10.1073/PNAS.93.13.6610
Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI.
S. Young (1996)
10.1039/A827019Z
Lanthanide(III) chelates for NMR biomedical applications
S. Aime (1998)
10.1039/A827043Z
The biomedical chemistry of technetium and rhenium
J. R. Dilworth (1998)
10.1002/(SICI)1521-3773(19990601)38:11<1512::AID-ANIE1512>3.0.CO;2-Y
Metals in Medicine.
Zijian Guo (1999)
10.1021/CR980441P
Metal-Based X-ray Contrast Media.
S. Yu. (1999)
10.1021/CR980436L
99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.
S. Liu (1999)
10.1021/CR980451Q
Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging
C. Anderson (1999)
10.1021/CR980435T
Potential technetium small molecule radiopharmaceuticals.
S. Jurisson (1999)
10.1021/CR980440X
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications.
P. Caravan (1999)
10.1002/1522-2594(200009)44:3<433::AID-MRM14>3.0.CO;2-9
Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles
S. Anderson (2000)
10.1021/JM000983A
[GdPCP2A(H2O)2]-: A Paramagnetic Contrast Agent Designed for Improved Applications in Magnetic Resonance Imaging
S. Aime (2000)
10.1021/IC000563B
Syntheses and relaxation properties of mixed gadolinium hydroxypyridinonate MRI contrast agents.
S. Cohen (2000)
10.1016/S0006-2952(99)00314-7
Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy.
J. Sessler (2000)
10.1038/73780
In vivo visualization of gene expression using magnetic resonance imaging
A. Louie (2000)
10.1021/BC000070V
Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals.
S. Liu (2001)
10.1021/JA0103647
pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation.
M. P. Lowe (2001)
10.1021/JA012668Z
An unusual dimeric structure of a Cu(I) bis(thiosemicarbazone) complex: implications for the mechanism of hypoxic selectivity of the Cu(II) derivatives.
A. Cowley (2002)
10.1007/3-540-45733-X_5
New Classes of MRI Contrast Agents
Vincent Jacques (2002)
10.1016/S0010-8545(02)00100-5
Biomedical uses and applications of inorganic chemistry. An overview
Nicholas Farrell (2002)
10.1007/3-540-45733-X_3
Relaxivity of MRI Contrast Agents
É. Tóth (2002)
10.1007/s00259-002-0900-8
Current use and future potential of organometallic radiopharmaceuticals
R. Schibli (2002)
10.1002/jmri.10180
Insights into the use of paramagnetic Gd(III) complexes in MR‐molecular imaging investigations
S. Aime (2002)
10.1021/IC0200390
Mechanistic studies of a calcium-dependent MRI contrast agent.
W. Li (2002)
10.1021/JA017168K
The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates.
P. Caravan (2002)
10.1021/IC0261575
The effect of ligand scaffold size on the stability of tripodal hydroxypyridonate gadolinium complexes.
B. O'sullivan (2003)
10.1016/j.conb.2003.09.009
New magnetic resonance contrast agents as biochemical reporters
T. Meade (2003)
10.1016/S0730-725X(03)00081-X
An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis.
M. E. Bartolini (2003)
10.1021/IC026240S
Toward optimized high-relaxivity MRI agents: the effect of ligand basicity on the thermodynamic stability of hexadentate hydroxypyridonate/catecholate gadolinium(III) complexes.
D. M. Doble (2003)
10.1021/BC0499681
Carbohydrate conjugates for molecular imaging and radiotherapy: 99mTc(I) and 186Re(I) tricarbonyl complexes of N-(2'-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose.
S. Bayly (2004)
10.1021/IC049028S
Gadolinium(III) 1,2-hydroxypyridonate-based complexes: toward MRI contrast agents of high relaxivity.
J. Xu (2004)
10.1021/IC0493447
Toward optimized high-relaxivity MRI agents: thermodynamic selectivity of hydroxypyridonate/catecholate ligands.
V. C. Pierre (2004)
10.1002/ANIE.200462400
All Science Is Interdisciplinary—From Magnetic Moments to Molecules to Men (Nobel Lecture)
P. Lauterbur (2005)
10.1002/ANIE.200502245
Multilocus binding increases the relaxivity of protein-bound MRI contrast agents.
Z. Zhang (2005)
10.1039/B313872K
Radiohalogens for imaging and therapy.
M. Adam (2005)
10.1021/BC049817Y
Next generation, high relaxivity gadolinium MRI agents.
K. Raymond (2005)
10.1039/B416040A
A glucosamine-dipicolylamine conjugate of 99mTc(I) and 186Re(I) for use in imaging and therapy.
T. Storr (2005)
10.1021/AR0400894
Benefiting from the unique properties of lanthanide ions.
Jean-Claude G Bünzli (2006)
10.2310/7290.2006.00026
Quantitative Imaging of Cell-Permeable Magnetic Resonance Contrast Agents Using X-Ray Fluorescence
Paul J H Endres (2006)
10.1021/JA065264L
A smart magnetic resonance contrast agent for selective copper sensing.
E. L. Que (2006)
10.1039/B416256K
Metal complexes of maltol and close analogues in medicinal inorganic chemistry.
K. Thompson (2006)
10.1039/B510982P
Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.
P. Caravan (2006)
10.1021/JA057954F
Tris(pyrone) chelates of Gd(III) as high solubility MRI-CA.
D. Puerta (2006)
10.1039/B514859F
Design of targeting ligands in medicinal inorganic chemistry.
T. Storr (2006)
10.1039/B705989B
Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.
A. Vāvere (2007)
10.1021/BC060269T
Use of lanthanide-grafted inorganic nanoparticles as effective contrast agents for cellular uptake imaging.
P. Voisin (2007)
10.1021/JM061324M
Toward improved syntheses of dendrimer-based magnetic resonance imaging contrast agents: new bifunctional diethylenetriaminepentaacetic acid ligands and nonaqueous conjugation chemistry.
H. Xu (2007)
10.1007/s00775-007-0215-0
A new bisphosphonate-containing 99mTc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation
E. Palma (2007)
10.1021/IC0702926
Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH.
F. Kálmán (2007)
10.1021/IC700686K
Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent.
P. Caravan (2007)
10.1002/ANIE.200700700
Collagen-targeted MRI contrast agent for molecular imaging of fibrosis.
P. Caravan (2007)
10.1007/s00775-007-0265-3
Multimodal MRI contrast agents
Luca Frullano (2007)
10.1021/BC700230M
Water-soluble contrast agents targeted at the estrogen receptor for molecular magnetic resonance imaging.
C. Gunanathan (2007)
10.1007/s00259-007-0603-2
Determinants of the response of left ventricular ejection fraction to vasodilator stress in electrocardiographically gated 82rubidium myocardial perfusion PET
T. Brown (2007)
10.2174/157488608783333989
Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.
M. Perazella (2008)
10.1021/ic702440e
Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity.
Z. Xiao (2008)
10.1021/bc8002919
Cell-permeable MR contrast agents with increased intracellular retention.
Paul J H Endres (2008)
10.1002/anie.200800212
High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging.
E. J. Werner (2008)
10.1039/b809365b
99m-Technetium carbohydrate conjugates as potential agents in molecular imaging.
M. Bowen (2008)
10.1021/cr0782426
Molecular imaging with PET.
S. Ametamey (2008)
10.1021/ja800834y
EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.
Kirsten Overoye-Chan (2008)
10.1097/RLI.0b013e3181852171
Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C
T. Frenzel (2008)
10.1021/bc700471z
99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer.
Jiyun Shi (2008)
10.1039/b717390c
A benzene-core trinuclear GdIII complex: towards the optimization of relaxivity for MRI contrast agent applications at high magnetic field.
J. B. Livramento (2008)
10.1039/b719704g
Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes.
P. Hermann (2008)
10.1016/j.nucmedbio.2008.10.010
Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine: potential agents for PET myocardial imaging with 68Ga.
Yui-May Hsiao (2009)
10.1021/ic801730u
1,2-hydroxypyridonate/terephthalamide complexes of gadolinium(III): synthesis, stability, relaxivity, and water exchange properties.
Eric J. Werner (2009)
10.1039/b819098d
A lysine walk to high relaxivity collagen-targeted MRI contrast agents.
P. Caravan (2009)
10.1021/ar800245h
Bioresponsive, cell-penetrating, and multimeric MR contrast agents.
Jody L. Major (2009)
10.1021/cr900325h
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.
T. Wadas (2010)



Semantic Scholar Logo Some data provided by SemanticScholar